As one selective, high-affinity, human immuno-globulin G1 monoclonal antibody, durvalumab has shown the promise for the treatment of patients with unresectable, stage III NSCLC by blocking PD-L1 binding to PD-1 and CD80 [7, 8]. Here, PDCD1 is linked to non-small cell lung carcinoma.